Table 1 Baseline characteristics of the TNFα-inhibitor and non-biologic cohorts at baseline
TNFα-inhibitor cohort | Non-biologic cohort | ||
|---|---|---|---|
Non-imputed | Non-imputed | ||
N= | 11995 | 3632 | |
Age | Years | 56 (12) | 60 (12) |
Gender | Female | 76 % | 73 % |
Ethnicity | White | 96 % | 98 % |
BMI | Kg.m−2 | 27.0 (7.1) | 27.4 (6.6) |
Smoking | Current | 22 % | 24 % |
Ex- | 38 % | 40 % | |
Never | 40 % | 37 % | |
DAS28 | 6.6 (1.0) | 5.1 (1.3) | |
TJC | 16 (7) | 8 (7) | |
SJC | 11 (6) | 6 (5) | |
ESR | 46 (29) | 35 (25) | |
VAS-GH | 73 (20) | 55 (24) | |
DAS28-P | 0.48 (0.07) | 0.44 (0.10) | |
Duration of RA | Years | 13 (10) | 10 (10) |
Serology | Positive | 65 % | 58 % |
Erosions | Yes | 63 % | 46 % |
Extra-articular | Yes | 29 % | 19 % |
Comorbidity | Yes | 60 % | 65 % |
HAQ | 2.0 (0.6) | 1.5 (0.8) | |
SF36-Vitality | 33 (10) | 39 (10) | |
SF36-Mental Health | 40 (11) | 45 (11) | |
SF36-Physical function | 16 (11) | 24 (14) | |
SF36-Bodily Pain | 25 (7) | 31 (9) | |
Steroids at baseline | 44 % | 23 % | |
DMARD at baseline | Methotrexate | 58 % | 65 % |
Sulphasalazine | 15 % | 32 % | |
Azathioprine | 2 % | 2 % | |
Leflunomide | 8 % | 12 % | |
D-penicillamine | 1 % | 1 % | |
Gold | 2 % | 5 % | |
Hydroxychloroquine | 10 % | 15 % | |
Ciclosporin | 1 % | 2 % | |
Cyclophosphamide | 0.10 % | 0.10 % | |